…and how recombinant production changes the equation.
The Pressure on Peptide and Protein Manufacturing Today
The peptide therapeutics market is surging. GLP-1 receptor agonists alone have reshaped global manufacturing demand, and behind them sits a pipeline of antimicrobial peptides, pepteins (41 to 100+ amino acids), complex disulfide-rich targets, and next-generation biologics that all need a viable production route. For CMC, process development, and procurement teams, the question is no longer whether peptides will be central to the pipeline. It is whether the manufacturing infrastructure can keep up.
Read the complete article: Numaferm_5 Reasons Peptide Programs stall before the molecule does